Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCSF
Dates
study started
completion around
Principal Investigator
by Pamela Munster (ucsf)
Headshot of Pamela Munster
Pamela Munster

Description

Summary

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.

Official Title

A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage Lymphoma Proto-oncogene (CBL-B) Inhibitor, in Adults With Advanced Malignancies, With Phase 1b Expansion in Select Tumor Types

Details

Keywords

Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic or Unresectable Melanoma, Non-small Cell Lung Cancer (NSCLC), Metastatic Castration-resistant Prostate Cancer (mCRPC), Malignant Pleural Mesothelioma (MPM), Triple Negative Breast Cancer (TNBC), Metastatic Urothelial Carcinoma, Cervical Cancer, Diffuse Large B Cell Lymphoma (DLBCL), Richter Transformation, Microsatellite Stable Colorectal Carcinoma, Ubiquitin Ligase Inhibitor, Advanced Malignancies, T-cell Activation, Lymphoma, Carcinoma, Neoplasms, Lymphoma, Large B-Cell, Diffuse, Triple Negative Breast Neoplasms, Mesothelioma, Malignant Mesothelioma, Squamous Cell Carcinoma of Head and Neck, Colorectal Neoplasms, Ovarian Epithelial Carcinoma, Paclitaxel

Eligibility

Locations

  • University of California, San Francisco accepting new patients
    San Francisco California 94158 United States
  • University of Southern California accepting new patients
    Los Angeles California 90007 United States

Lead Scientist at University of California Health

  • Pamela Munster (ucsf)
    Professor, Medicine, School of Medicine. Authored (or co-authored) 161 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Nurix Therapeutics, Inc.
ID
NCT05107674
Phase
Phase 1 research study
Study Type
Interventional
Participants
Expecting 345 study participants
Last Updated